Naoi Yasuto, Miyoshi Yasuo, Taguchi Tetsuya, Kim Seung Jin, Arai Takashi, Tamaki Yasuhiro, Noguchi Shinzaburo
Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita-shi, Osaka, 565-0871, Japan.
Breast Cancer Res Treat. 2007 Nov;106(1):11-7. doi: 10.1007/s10549-006-9465-8. Epub 2007 Jan 3.
Cx26, which is a constituent of the connexin family, has recently been shown to promote metastasis through enhancing the vascular invasion in mouse melanoma cells. In this study, we have investigated whether or not Cx26 expression is associated with vascular invasion and recurrences in human breast cancers.
Cx26 expression was studied in 152 invasive breast cancers by immunohistochemistry. In order to investigate the blood vessel invasion and lymphatic vessel invasion with precision, immunohistochemical staining of blood vessels and lymphatic vessels was carried out using anti-CD34 and anti-D2-40 antibodies, respectively.
Cx26 was positive in 51.3% (78/152) of the breast tumors. A statistically significant association was observed between Cx26 expression and large tumor size (P = 0.013) or high histological grade (P = 0.043). Frequency of blood vessel invasion was higher in Cx26-positive tumors (5.1%, 4/78) than in Cx26-negative tumors (1.4%, 1/74) though not statistically significant (P = 0.210). Lymphatic vessel invasion was significantly (P = 0.001) more frequent in Cx26-positive tumors (39.7%) than in Cx26-negative tumors (14.9%). Patients with Cx26-positive tumors showed a significantly (P < 0.001) poorer prognosis than those with Cx26-negative tumors. Multivariate analysis showed that Cx26 (P < 0.05) expression was an independent prognostic factor.
Cx26 expression is associated with lymphatic vessel invasion, large tumor size, high histological grade, and poor prognosis in human breast cancers. Cx26 seems to enhance the metastasis probably through promoting the lymphatic vessel invasion. Cx26 might be clinically useful as a new prognostic factor.
连接蛋白家族成员Cx26最近被证明可通过增强小鼠黑色素瘤细胞的血管侵袭来促进转移。在本研究中,我们调查了Cx26表达是否与人类乳腺癌的血管侵袭和复发相关。
通过免疫组织化学研究了152例浸润性乳腺癌中Cx26的表达。为了精确研究血管侵袭和淋巴管侵袭,分别使用抗CD34和抗D2-40抗体对血管和淋巴管进行免疫组织化学染色。
51.3%(78/152)的乳腺肿瘤中Cx26呈阳性。观察到Cx26表达与肿瘤体积大(P = 0.013)或组织学分级高(P = 0.043)之间存在统计学显著关联。Cx26阳性肿瘤的血管侵袭频率(5.1%,4/78)高于Cx26阴性肿瘤(1.4%,1/74),但无统计学意义(P = 0.210)。Cx26阳性肿瘤的淋巴管侵袭显著更频繁(P = 0.001)(39.7%),高于Cx26阴性肿瘤(14.9%)。Cx26阳性肿瘤患者的预后明显(P < 0.001)比Cx26阴性肿瘤患者差。多变量分析表明Cx26(P < 0.05)表达是一个独立的预后因素。
Cx26表达与人类乳腺癌的淋巴管侵袭、肿瘤体积大、组织学分级高及预后差相关。Cx26似乎可能通过促进淋巴管侵袭来增强转移。Cx26可能作为一种新的预后因素具有临床应用价值。